Literature DB >> 9886103

Malaria situation in several villages around Timika, south central Irian Jaya, Indonesia.

W Pribadi1, I Sutanto, S Atmosoedjono, R Rasidi, L K Surya, L Susanto.   

Abstract

Malaria in Timika area, south central Irian Jaya, is a public health problem causing morbidity and mortality, particularly to the vulnerable age group. In August/September 1992 malariometric surveys were conducted simultaneously with sensitivity studies of Plasmodium falciparum to antimalarials, and bionomics of vectors in six villages around Timika (Mwapi, Kaugapu, Hiripau, Pomako, Mapurujaya, Kwamki Lama). The average overall spleen rate was 44.0%, the highest rate observed in Kwamki Lama (68.3%) and the lowest in Mapurujaya (13.7%). The average parasite rate in children aged 2-9 years was 60.6%. The highest rate was found in Mwapi (92.0%) and the lowest rate in Mapurujaya (4.8%). In the study area the dominant species was P. falciparum, (except in Kaugapu), followed by P. vivax. P. malariae and P. ovale were not observed. In vivo sensitivity studies done in 7 villages showed P. falciparum was resistant to chloroquine [51.3% S/R I (sensitive or 1st grade resistant), 43.6% R II and 5.1% R III] in Kwamki Lama, SP I and SP II (transmigrant settlements) and Timika health service center. In vitro sensitivity test in Kwamki Lama, SP I, SP II and Timika health service center showed 64.4% resistant to chloroquine, and remain sensitive to sulfadoxine-pyrimethamine, quinine and mefloquine. Vector studies revealed that Anophelese punctulatus and An. koliensis were the potential vectors as was confirmed by ELISA positive test with a sporozoite rate of 1.43% and 0.33% respectively. The vectors were indoor and outdoor resting.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9886103

Source DB:  PubMed          Journal:  Southeast Asian J Trop Med Public Health        ISSN: 0125-1562            Impact factor:   0.267


  11 in total

1.  The dominant Anopheles vectors of human malaria in the Asia-Pacific region: occurrence data, distribution maps and bionomic précis.

Authors:  Marianne E Sinka; Michael J Bangs; Sylvie Manguin; Theeraphap Chareonviriyaphap; Anand P Patil; William H Temperley; Peter W Gething; Iqbal R F Elyazar; Caroline W Kabaria; Ralph E Harbach; Simon I Hay
Journal:  Parasit Vectors       Date:  2011-05-25       Impact factor: 3.876

2.  Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine-pyrimethamine in vivax malaria pilot studies: relationship to Plasmodium vivax dhfr mutations.

Authors:  Emiliana Tjitra; Joanne Baker; Sri Suprianto; Qin Cheng; Nicholas M Anstey
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

Review 3.  Malaria distribution, prevalence, drug resistance and control in Indonesia.

Authors:  Iqbal R F Elyazar; Simon I Hay; J Kevin Baird
Journal:  Adv Parasitol       Date:  2011       Impact factor: 3.870

4.  In vivo and in vitro efficacy of chloroquine against Plasmodium malariae and P. ovale in Papua, Indonesia.

Authors:  H Siswantoro; B Russell; A Ratcliff; B Prasetyorini; F Chalfein; J Marfurt; E Kenangalem; M Wuwung; K A Piera; E P Ebsworth; N M Anstey; E Tjitra; R N Price
Journal:  Antimicrob Agents Chemother       Date:  2010-10-11       Impact factor: 5.191

5.  Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison.

Authors:  A Ratcliff; H Siswantoro; E Kenangalem; R Maristela; R M Wuwung; F Laihad; E P Ebsworth; N M Anstey; E Tjitra; R N Price
Journal:  Lancet       Date:  2007-03-03       Impact factor: 79.321

6.  Evaluation of chloroquine therapy for vivax and falciparum malaria in southern Sumatra, western Indonesia.

Authors:  Inge Sutanto; Dedeh Endawati; Liem Hui Ling; Ferdinand Laihad; Rianto Setiabudy; J Kevin Baird
Journal:  Malar J       Date:  2010-02-12       Impact factor: 2.979

7.  In vivo and in vitro efficacy of amodiaquine monotherapy for treatment of infection by chloroquine-resistant Plasmodium vivax.

Authors:  A R Hasugian; E Tjitra; A Ratcliff; H Siswantoro; E Kenangalem; R M Wuwung; H L E Purba; K A Piera; F Chalfien; J Marfurt; P M Penttinen; B Russell; N M Anstey; R N Price
Journal:  Antimicrob Agents Chemother       Date:  2008-12-22       Impact factor: 5.191

8.  Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria.

Authors:  A R Hasugian; H L E Purba; E Kenangalem; R M Wuwung; E P Ebsworth; R Maristela; P M P Penttinen; F Laihad; N M Anstey; E Tjitra; R N Price
Journal:  Clin Infect Dis       Date:  2007-03-05       Impact factor: 9.079

9.  Malaria morbidity in Papua Indonesia, an area with multidrug resistant Plasmodium vivax and Plasmodium falciparum.

Authors:  Muhammad Karyana; Lenny Burdarm; Shunmay Yeung; Enny Kenangalem; Noah Wariker; Rilia Maristela; Ketut Gde Umana; Ram Vemuri; Maurits J Okoseray; Pasi M Penttinen; Peter Ebsworth; Paulus Sugiarto; Nicholas M Anstey; Emiliana Tjitra; Richard N Price
Journal:  Malar J       Date:  2008-08-02       Impact factor: 2.979

10.  Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia.

Authors:  A Ratcliff; H Siswantoro; E Kenangalem; M Wuwung; A Brockman; M D Edstein; F Laihad; E P Ebsworth; N M Anstey; E Tjitra; R N Price
Journal:  Trans R Soc Trop Med Hyg       Date:  2006-10-09       Impact factor: 2.184

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.